Subscribe to our Newsletters !!
Drug quality is defined not only how a drug is man
It is undeniable what the history different has wi
The journey and merging of sperm and egg cells is
This year, the Hamburg based life sciences company
Cipla Limited (BSE: 5
Since it’s an ingredient in so many foods, you h
In a world constantly in motion, Microbioz India r
The Hyderabad-based firm has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy”s Laboratories said in a statement.
In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a permit to sell volume-limited amounts of generic lenalidomide capsules in america starting on a confidential date after March 2022 subject to regulatory approval, it added.
The agreed-upon proportions are confidential, Dr Reddy”s said.
The drug maker is already licensed to sell generic lenalidomide capsules in the US without volume limitation starting on January 31, 2026, Dr Reddy”s said.
“We are satisfied with the settlement agreement, and look forward to bringing a generic version of lenalidomide to market shortly subject to regulatory approval for the benefit of patients,” Dr Reddy”s Laboratories North America Generics CEO Marc Kikuchi said.
Revlimid, a trademark of Celgene, is used in the treatment of multiple myeloma and myelodysplastic syndromes. PTI MSS RVK
